Difference between revisions of "Fotemustine (Muphoran)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "==Mechanism of action== From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=38865 NCI Drug Dictionary]: A chloroethylating nitrosourea with antineoplas...")
 
m
(12 intermediate revisions by 3 users not shown)
Line 2: Line 2:
 
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=38865 NCI Drug Dictionary]: A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.
 
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=38865 NCI Drug Dictionary]: A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.
  
−
==Preliminary data==
+
==Diseases for which it is used==
 +
*[[Diffuse large B-cell lymphoma]]
 +
*[[Classical Hodgkin lymphoma]]
 +
*[[Melanoma]]
 +
**[[CNS melanoma]]
 +
**[[Uveal melanoma]]
  
−
===[[Hodgkin lymphoma]]===
+
==History of changes in EMA indication==
−
# Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. Br J Haematol. 2016 Jan;172(1):111-21. Epub 2015 Oct 12. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13803/full link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/26458240 PubMed]
+
*1989-04-14: EURD
 +
==Also known as==
 +
*'''Brand names:''' Muphoran, Mustophoran
  
−
===[[Transplant conditioning regimens]]===
+
[[Category:Drugs]]
−
# Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, Di Bartolomeo P, Crescimanno A, Perrone T, Pinto A. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant. 2010 Jul;45(7):1147-53. Epub 2009 Nov 9. [http://www.nature.com/bmt/journal/v45/n7/full/bmt2009318a.html link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/19898504 PubMed]
+
[[Category:Intravenous medications]]
 +
[[Category:Nitrosoureas]]
  
−
[[Category:Drug index]]
+
[[Category:Diffuse large B-cell lymphoma medications]]
−
[[Category:Chemotherapy]]
+
[[Category:Classical Hodgkin lymphoma medications]]
−
[[Category:Intravenous chemotherapy]]
+
[[Category:Melanoma medications]]
−
[[Category:Nitrosureas]]
+
[[Category:Uveal melanoma medications]]
  
−
[[Category:Hodgkin lymphoma medications]]
+
[[Category:EMA approved in 1989]]
−
[[Category:Transplant medications]]
 
−
 
 
−
[[Category:Investigational]]
 

Revision as of 11:56, 11 June 2023

Mechanism of action

From the NCI Drug Dictionary: A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.

Diseases for which it is used

History of changes in EMA indication

  • 1989-04-14: EURD

Also known as

  • Brand names: Muphoran, Mustophoran
Retrieved from "https://hemonc.org/w/index.php?title=Fotemustine_(Muphoran)&oldid=73196"